Was Uri Geiger’s 789-share NeuroPace transaction an open-market purchase?

The 789-share transaction was not an open-market purchase. The shares were issued to Uri Geiger under NeuroPace’s non-employee director compensation policy in lieu of quarterly retainer fees, making it a compensation-related stock award rather than a market trade.

NeuroPace (NPCE) director granted 789 shares as quarterly fee award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NeuroPace director Uri Geiger received a stock award of 789 shares of common stock at $15.63 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, so this is a routine compensation-related acquisition rather than an open-market purchase.

After this award, Geiger holds 18,537 NeuroPace shares directly. Separately, 4,432,948 shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power via his role at Accelmed Partners II, LLC.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Geiger Uri

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	789	$15.63	$12K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 18,537 shares (Direct, null); Common Stock — 4,432,948 shares (Indirect, See footnote)

Footnotes (1)

These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

Key Figures

Director stock award: 789 shares Grant price: $15.63 per share Direct holdings after award: 18,537 shares +1 more

4 metrics

Director stock award 789 shares Common stock grant in lieu of quarterly retainer fees

Grant price $15.63 per share Price used for the 789-share director award

Direct holdings after award 18,537 shares NeuroPace common stock directly owned by Uri Geiger after the grant

Indirect holdings via Accelmed Partners II LP 4,432,948 shares Shares held indirectly where Geiger has sole voting and dispositive power

Key Terms

non-employee director compensation policy, quarterly retainer fees, voting and dispositive power, indirect ownership

4 terms

non-employee director compensation policy financial

"These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees."

quarterly retainer fees financial

"pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees."

voting and dispositive power financial

"Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP."

indirect ownership financial

"Shares are held by Accelmed Partners II LP... has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:34 PM Accepted by SEC EDGAR 06/22/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geiger Uri

(Last)

(First)

(Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW

CALIFORNIA

94043

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/19/2026		A		789⁽¹⁾	A	$15.63	18,537	D
Common Stock								4,432,948	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

2. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did NeuroPace (NPCE) director Uri Geiger report in this Form 4?

Director Uri Geiger reported receiving 789 shares of NeuroPace common stock as a stock award. These shares were granted under the non-employee director compensation policy, replacing his quarterly cash retainer, and increased his directly held stake in the company.

How many NeuroPace shares did Uri Geiger receive and at what price?

Uri Geiger received 789 NeuroPace common shares at $15.63 per share. The award reflects a routine director compensation grant, issued in stock instead of paying his quarterly board retainer in cash under the company’s non-employee director policy.

What is Uri Geiger’s direct NeuroPace shareholding after this grant?

After the 789-share award, Uri Geiger directly holds 18,537 NeuroPace common shares. This figure reflects only his personal, direct ownership and excludes additional shares that are held indirectly through investment entities associated with him.

How many NeuroPace shares does Uri Geiger control indirectly through Accelmed Partners II LP?

Entities associated with Uri Geiger hold 4,432,948 NeuroPace shares indirectly through Accelmed Partners II LP. Geiger, as managing partner of Accelmed Partners II, LLC, has sole voting and dispositive power over these shares according to the disclosed ownership footnote.